During her annual OB-GYN visit, Callie Anderson asked about getting off the birth control pill. “We decided the best option for me was an IUD,” she said, referring to an intrauterine device, a long-acting, reversible type of birth control. Anderson, 25, of Scranton, Pennsylvania, asked her doctor how much it might cost. At the time,…
Threats of a federal government shutdown have gone from being an October surprise to a recurring theme. This time around, though, the stakes are higher. Federal funding ran out at midnight on Oct. 1, after Congress failed to pass even a stopgap budget while negotiations continued. Now the question is how long the deadlock will…
GEM HEALTH’s Series A round was co-led by HealthTrend Capital and LFE Capital and included participation from existing investors Base10 Partners and Mairs & Power Venture Capital. The post GEM HEALTH Secures $7M to Advance Virtual Sleep Care appeared first on MedCity News.
In today’s healthcare landscape, credibility doesn’t come from an agency logo. It comes from an idea that lands, a brand platform that manifests quickly, and results that speak for themselves. The post Your Healthcare Startup Is Built for Speed and Agility — Your Agency Should Be Too appeared first on MedCity News.
Clinical trials, real-world data and digital biomarkers are turning artificial intelligence into a practical ally in the fight against depression. The post How AI Is Helping Psychiatrists Make Faster, Smarter Treatment Decisions appeared first on MedCity News.
This volume examines findings about trusted sources of vaccine information from the latest KFF Tracking Poll on Health Information and Trust. It also explores how the misrepresentation of studies and policy developments contribute to health narratives around vaccines, HIV and PrEP. Lastly, it summarizes new research on the use of generative AI to counteract vaccine…
In the dim basement of a Salt Lake City pharmacy, hundreds of amber-colored plastic pill bottles sit stacked in rows, one man’s defensive wall in a tariff war. Independent pharmacist Benjamin Jolley and his colleagues worry that the tariffs, aimed at bringing drug production to the United States, could instead drive companies out of business…
AI doesn’t need to be a black box — and hospitals don’t need to invest based on blind faith. With the right structure, questions, and metrics in place, healthcare leaders can cut through the hype and make decisions that actually drive value. The post Hospitals Are Investing in AI — How Can They Evaluate ROI?…
The decline in cognitive health, especially that leading to Alzheimer’s and other brain diseases, is one of the most feared conditions by patients and their families. It’s also one of the most expensive. But if we can predict it early there are things we can do to prevent or ameliorate it. The issue has been…
Revenue for the blockbuster Eli Lilly drugs Mounjaro and Zepbound continues to grow, but not as much as expected. At the J.P. Morgan Healthcare Conference, Lilly CEO David Ricks explained why the company revised downward its projections for fourth quarter 2024 revenue. The post At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were…